De-escalating or Stopping DMT in a 67-Year-Old MS Patient
In a 67-year-old patient with MS, consider discontinuing DMT if they have had no clinical relapses, no new MRI lesions, and stable disability for at least 2-5 years, particularly if they are on first-line therapy and have an EDSS ≤6.0. However, age alone should not be the sole criterion—the decision must be driven by documented disease stability, not just chronological age 1, 2.
Key Criteria for DMT Discontinuation
Clinical Stability Requirements
- No relapses for ≥2-5 years prior to discontinuation
- No new or gadolinium-enhancing MRI lesions in the final year on DMT
- Stable EDSS score (preferably ≤6.0) without progression
- No recent inflammatory activity (clinical or radiological) in the preceding 12 months 2, 3
Patient Characteristics Favoring Discontinuation
- Age considerations: While 67 falls into the older MS population, age >60 years with stable disease shows minimal MRI reactivation after discontinuation 2
- Disease duration: Longer disease duration (>10-20 years) with prolonged stability
- DMT type: First-line DMTs (interferons, glatiramer acetate) are safer to discontinue than high-efficacy DMTs 2
- Secondary progressive MS without inflammatory activity: These patients derive less benefit from continued DMT 4
High-Risk Features That Argue AGAINST Discontinuation
- Recent MRI activity (within past year)—this is the strongest predictor of post-discontinuation reactivation 2
- Recent clinical relapses (within 2-5 years)
- High-efficacy DMT use (natalizumab, fingolimod, alemtuzumab, ocrelizumab)—these carry significant rebound risk 1, 5
- Younger biological age with active inflammatory disease
- Short disease duration (<10 years) 4
Monitoring Protocol After Discontinuation
If discontinuation proceeds, implement strict surveillance:
MRI monitoring: Obtain baseline MRI at discontinuation, then every 6-12 months for at least 2 years 6
- Use T2-FLAIR and T2-weighted sequences minimum
- Consider gadolinium-enhanced T1 if any clinical concern arises
Clinical monitoring: Assess every 3-6 months for:
- New neurological symptoms
- EDSS changes
- Cognitive function
Immediate reinitiation criteria:
Critical Caveats by DMT Type
High-Efficacy DMTs Require Special Consideration
Natalizumab and fingolimod: Never abruptly discontinue—these carry severe rebound risk with disease activity potentially exceeding pre-treatment levels. If stopping is necessary, bridge to another DMT 6, 5
Anti-CD20 therapies (ocrelizumab, rituximab): May have prolonged B-cell depletion allowing for extended monitoring intervals, but rebound can still occur 5
Alemtuzumab and cladribine: These immune reconstitution therapies may allow for treatment-free intervals by design, but require ongoing autoimmune surveillance 5
First-Line DMTs
Interferons, glatiramer acetate, teriflunomide, and dimethyl fumarate can be discontinued more safely in stable patients without bridging therapy 2
Practical Algorithm for This 67-Year-Old Patient
Assess current disease activity:
- Obtain brain MRI with gadolinium within past 6 months
- Review relapses in past 5 years
- Document current EDSS and compare to 2-year-old baseline
If ALL criteria met (no relapses ≥2 years, no MRI activity ≥1 year, stable EDSS, on first-line DMT):
- Proceed with discontinuation
- Schedule 6-month MRI follow-up
- Clinical assessment every 3-6 months
If on high-efficacy DMT or any recent activity:
- Do not discontinue
- Consider de-escalation to moderate-efficacy DMT only if compelling reason (adverse effects, comorbidities)
- Maintain current therapy if well-tolerated
If pre-discontinuation MRI shows activity:
- Absolute contraindication to stopping—this is the strongest predictor of post-discontinuation reactivation 2
Comorbidity Considerations
At age 67, cardiovascular disease burden increases. While MS patients have higher CVD risk, there is no clear evidence that DMTs themselves improve cardiovascular outcomes 5. Balance polypharmacy risks against MS reactivation risk—but prioritize MS stability over theoretical polypharmacy concerns if disease remains active.
The presence of frailty, disability, or significant comorbidities paradoxically correlates with LOWER discontinuation rates in real-world data, suggesting clinicians appropriately maintain therapy in more vulnerable patients 7.
What NOT to Do
- Never discontinue based solely on age—biological disease activity trumps chronological age
- Never stop high-efficacy DMTs abruptly without bridging strategy
- Never discontinue without baseline MRI for future comparison
- Never extend monitoring intervals beyond 6-12 months in the first 2 years post-discontinuation
The evidence from recent trials (DISCOMS, DOT-MS) shows disease reactivation risk after discontinuation, though these studies had limited power for age-stratified analyses 5. The safest approach remains continuation of therapy in patients with any residual inflammatory activity, regardless of age.